Qulipta (atogepant) is FDA approved for both chronic and episodic migraine prevention in adults. New data shows promising results in patients who've failed multiple other preventives.

New migraine treatments have brought stunning relief to many people by blocking the action of calcitonin gene-related peptide (CGRP), a protein in the brain involved in the migraine process. But while ...

Infusions of ketamine are an effective, safe, and well tolerated option for severe, refractory headache in children, ...

CGRP inhibitors have been elevated to a first-line prevention method for migraine ... potentially offering a promising avenue for relief, according to a new position statement.

While there was a breakthrough for the treatment of migraines yesterday, the journey to find a cure has been long, but while there is still no ‘magic bullet’ the news will still have a dramatic impact ...

A new daily pill that can effectively reduce the frequency of migraine attacks has been approved for use by NICE ...

DENVER -- No new safety signals emerged with daily atogepant (Qulipta) for migraine prevention, an interim analysis of a long ...

‘We now need to ensure access is swift, so that migraine patients can benefit from them as quickly as possible.” More than 170,000 people could benefit from the new treatment ...

Among U.S. women with migraine, a third say the attacks tend to coincide with their periods, a new survey finds ... There are treatments that can help and if the first treatment tried does ...

When you're in pain from a migraine headache, you need relief. The medical professionals at Physical Medicine are here to ...

A new drug designed to prevent migraines is to become available on the NHS in Wales after recommendation from Nice. Atopgepant is an oral treatment that prevents chronic and episodic migraines.